Asunto(s)
Carcinoma de Células Renales/terapia , Interleucina-2/uso terapéutico , Neoplasias Renales/terapia , Anciano , Carcinoma de Células Renales/patología , Evaluación de Medicamentos , Femenino , Humanos , Interleucina-2/efectos adversos , Neoplasias Renales/patología , Masculino , Persona de Mediana Edad , Proteínas RecombinantesRESUMEN
Natural interleukin-2 is a lymphokine with an immunoregulatory function. The recombinant interleukin-2 (rIL-2) is cloned from a human lymphoblastoid T-cell line for this trial. The gene is expressed in E-coli, allowing production of large quantities of rIL-2. This study is an open label phase I-II trial designed to evaluate the toxicity and efficacy of a rIL-2 in disseminated renal cell carcinoma. After surgical resection of the primary tumor, 3 X 10(6) units/m2 day rIL-2 is administered by 2-hr IV infusions daily for 5 days every other week for a total of eight cycles. At the conclusion of eight cycles of therapy, the patients were re-evaluated for response. Patients with complete and partial responses were eligible to receive an additional eight cycles every other week. Patients demonstrating progressive disease during this study were withdrawn. The toxicities of the high-dose rIL-2 included transient hypotension, pyrexia, malaise, and skin rashes. The transient hypotension responded to fluid replacement, and the other toxicities also responded to symptomatic treatment. The early results in ten patients indicate two partial and one complete response. We have concluded that administration of high-dose interleukin-2 has acceptable toxicities with encouraging response and deserves a phase III study.
Asunto(s)
Carcinoma de Células Renales/secundario , Interleucina-2/administración & dosificación , Adulto , Anciano , Carcinoma de Células Renales/terapia , Terapia Combinada , Esquema de Medicación , Evaluación de Medicamentos , Femenino , Humanos , Infusiones Intravenosas , Neoplasias Renales/cirugía , Masculino , Persona de Mediana Edad , Nefrectomía , Proteínas Recombinantes , Inducción de RemisiónRESUMEN
During the past two decades, a dramatic improvement has been made in the treatment of testicular germ cell tumor. This progress has been due to finding more efficacious systemic chemotheraeutic agents and the availability of specific and sensitive biologic tumor markers to detect early recurrence and monitor the therapy. In this review, I will update my 15 years of experience in establishing and utilization of these serum and cell markers in testicular cancer
Asunto(s)
Humanos , Masculino , Suero Antilinfocítico , Biomarcadores de Tumor/sangre , Neoplasias Testiculares/sangreRESUMEN
A case of isolated traumatic avulsion of the tendon of extensor carpi radialis longus (ECRL) is described. Surgical repair was attempted 12 days later, but an early contracture of the muscle was encountered. The tendon could not be pulled down to its insertion and was sutured side to side to the tendon of extensor carpi radialis brevis (ECRB). A year later the patient had residual weakness of wrist extension and hand grip. The likely cause of the early contracture of the muscle and the need for early and accurate reposition of extensor carpi radialis longus tendon are described.